Pharmaceuticals

Global Biosimilar Hormones Market Forecast 2026–2035

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Biosimilar Hormones Market By 2030 Starting From Its 2026 Size?

The biosimilar hormones market has witnessed remarkable expansion recently. This market is projected to expand from $6.22 billion in 2025 to $7.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.5%. Historically, this growth has been fueled by factors such as the rising incidence of diabetes and hormonal conditions, the high cost of branded hormone therapies, an increasing aging population, growing awareness of hormone replacement therapies, and the expansion of hospital and retail pharmacy networks.

The market for biosimilar hormones is projected to experience rapid expansion over the upcoming years. By 2030, this market is anticipated to reach a valuation of $18.12 billion, advancing at a compound annual growth rate (CAGR) of 23.9%. This anticipated growth is driven by several factors, including the expiration of patents for key biologic hormones, enhanced regulatory backing for biosimilars, a burgeoning need for economical endocrine therapies, the proliferation of online pharmacy outlets, and increasing capital directed towards biosimilar research and development. Key developments expected during this period involve the increasing embrace of biosimilar hormones as economical options, a surge in the need for insulin and growth hormone biosimilars, greater physician acceptance of biosimilar hormone treatments, the broadening application of biosimilars in managing chronic and lifestyle conditions, and enhanced regulatory processes facilitating biosimilar authorizations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Biosimilar Hormones Market?

The biosimilar hormones market is anticipated to grow due to the increasing healthcare expenditure. This expenditure refers to the total financial outlay by individuals, organizations, or governments to prevent, treat, and manage health conditions. Healthcare spending is rising as a result of advancements in medical technology, where new diagnostic tools, treatments, and innovative therapies often come with higher price tags, contributing to increased overall spending in healthcare. Greater healthcare expenditure boosts the use of biosimilar hormones by creating demand for more cost-effective therapies and improving patient access across various healthcare systems. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, reported that U.S. health care expenditures rose by 7.5% in 2023, reaching $4.9 trillion, which is roughly $14,570 per individual. Therefore, the escalating healthcare expenditure is driving the expansion of the biosimilar hormones market.

Which Segment Categories Define The Biosimilar Hormones Market?

The biosimilar hormones market covered in this report is segmented –

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types

2) By Application: Research & Biotechnology, Therapeutics, Other Applications

3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics

Subsegments:

1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance

2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)

3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management

4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders

5) By Other Types: Thyroid Hormones, Corticosteroids

What Major Market Trends Are Driving Changes In The Biosimilar Hormones Market?

Leading firms within the biosimilar hormones market are developing novel products, including the Sogroya (somapacitan-beco) injection, with the aim of boosting their market profitability. Sogroya (somapacitan-beco) serves as a prescription-based analog of human growth hormone (GH), employed for treating individuals afflicted with growth hormone deficiency (GHD). For example, in April 2023, Novo Nordisk, a pharmaceutical entity based in Denmark, secured FDA approval for an expanded use of the Sogroya (somapacitan-beco) injection. This new indication is for managing growth failure in children 2.5 years of age and above, caused by inadequate endogenous growth hormone secretion. Uniquely, Sogroya is the only once-weekly growth hormone (GH) treatment available for both pediatric and adult patients. This approval was predicated on the results from the phase 3 REAL4 trial, which confirmed Sogroya’s efficacy in addressing growth hormone deficiency (GHD) in pediatric populations.

Who Are The Top Companies Competing In The Biosimilar Hormones Market?

Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy’s Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

Read the full biosimilar hormones market report here:

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Which Regions Are Projected To Dominate The Biosimilar Hormones Market In The Coming Years?

North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biosimilar Hormones Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3432&type=smp

Browse Through More Reports Similar to the Global Biosimilar Hormones Market 2026, By The Business Research Company

Hormonal Contraceptives Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

Biosimilar Growth Hormone Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Parathyroid Hormones Market Report 2026

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795